Look up one drug

Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Lanthanum Brand(s): Fosrenol and Generics DOSAGE FORM/ STRENGTH: 250 mg, 500 mg, 750 mg, 1000 mg Chewable tablet Sevelamer Hydrochloride Brand(s): Renagel DOSAGE FORM/ STRENGTH: 800 mg tablet Sevelamer Carbonate Brand(s): Accel-Sevelamer DOSAGE FORM/ STRENGTH: 800 mg tablet Sevelamer Carbonate Brand(s): Renvela DOSAGE FORM/ STRENGTH: 800 mg tablet, 0.8 g powder sachet, 2.4 g powder sachet Updated: June 7, 2021 i) For the treatment of hyperphosphatemia associated with end-stage renal disease (ESRD) where patients are on dialysis and have a sustained serum phosphate > 1.8 mmol/L AND adjusted serum calcium > 2.65 mmol/L; OR ii) For dialysis patients experiencing hyperphosphatemia (sustained serum phosphate levels >1.8 mmol/L) who have calciphylaxis and/or evidence of coronary artery calcification. 466 Notes: 1. Calcium and phosphate levels provided to demonstrate sustained elevations should be at least 4 weeks apart. 2. Patients who demonstrate reduction of phosphate levels while on a calcium binder but who experience adjusted serum calcium > 2.65 mmol/L must provide supporting laboratory levels before treatment and while on treatment and should include the dose(s) of calcium-based binder used. Exclusion Criteria: Sevelamer will not be reimbursed in the following cases: Use in combination therapy with another funded non-calcium-based phosphate binder (e.g. lanthanum carbonate hydrate, sucroferric oxyhydroxide, other sevelamer formulations) Duration of approval: lifetime On a case-by-case basis, requests may be considered for sevelamer under the EAP for a patient with serum phosphate less than 1.8mmol/L and calcium values less than 2.65 mmol/L. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 466, record 303, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Nat-Lanthanum · DIN 02498731 Manufacturer: Natco Pharma (Canada) Inc.; listing date 2020-08-28 Health Canada: Marketed since 2020-07-21 · brand NAT-LANTHANUM · ATC V03AE03 LANTHANUM CARBONATE · form Tablet (chewable) · route Oral · ingredients LANTHANUM (LANTHANUM CARBONATE DIHYDRATE) 250 MG · company Natco pharma (canada) inc · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02498731). DIN 02498731: Nat-Lanthanum Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 401800005; group id 550; item number 1482; lccId None; manufacturer id NAT Source form: Chew Tab; strength: 250mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $1.2034; ministry $1.2034 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02498731 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98843

Interchangeable products

Fosrenol · DIN 02287145 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02498731

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Lanthanum Brand(s): Fosrenol and Generics DOSAGE FORM/ STRENGTH: 250 mg, 500 mg, 750 mg, 1000 mg Chewable tablet Sevelamer Hydrochloride Brand(s): Renagel DOSAGE FORM/ STRENGTH: 800 mg tablet Sevelamer Carbonate Brand(s): Accel-Sevelamer DOSAGE FORM/ STRENGTH: 800 mg tablet Sevelamer Carbonate Brand(s): Renvela DOSAGE FORM/ STRENGTH: 800 mg tablet, 0.8 g powder sachet, 2.4 g powder sachet Updated: June 7, 2021 i) For the treatment of hyperphosphatemia associated with end-stage renal disease (ESRD) where patients are on dialysis and have a sustained serum phosphate > 1.8 mmol/L AND adjusted serum calcium > 2.65 mmol/L; OR ii) For dialysis patients experiencing hyperphosphatemia (sustained serum phosphate levels >1.8 mmol/L) who have calciphylaxis and/or evidence of coronary artery calcification. 466 Notes: 1. Calcium and phosphate levels provided to demonstrate sustained elevations should be at least 4 weeks apart. 2. Patients who demonstrate reduction of phosphate levels while on a calcium binder but who experience adjusted serum calcium > 2.65 mmol/L must provide supporting laboratory levels before treatment and while on treatment and should include the dose(s) of calcium-based binder used. Exclusion Criteria: Sevelamer will not be reimbursed in the following cases: Use in combination therapy with another funded non-calcium-based phosphate binder (e.g. lanthanum carbonate hydrate, sucroferric oxyhydroxide, other sevelamer formulations) Duration of approval: lifetime On a case-by-case basis, requests may be considered for sevelamer under the EAP for a patient with serum phosphate less than 1.8mmol/L and calcium values less than 2.65 mmol/L. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 466, record 303, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Nat-Lanthanum · DIN 02498758 Manufacturer: Natco Pharma (Canada) Inc.; listing date 2020-07-31 Health Canada: Marketed since 2020-07-21 · brand NAT-LANTHANUM · ATC V03AE03 LANTHANUM CARBONATE · form Tablet (chewable) · route Oral · ingredients LANTHANUM (LANTHANUM CARBONATE DIHYDRATE) 500 MG · company Natco pharma (canada) inc · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02498758). DIN 02498758: Nat-Lanthanum Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 401800006; group id 550; item number 1483; lccId None; manufacturer id NAT Source form: Chew Tab; strength: 500mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $2.4069; ministry $2.4069 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02498758 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98844

Interchangeable products

Fosrenol · DIN 02287153 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02498758

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Lanthanum Brand(s): Fosrenol and Generics DOSAGE FORM/ STRENGTH: 250 mg, 500 mg, 750 mg, 1000 mg Chewable tablet Sevelamer Hydrochloride Brand(s): Renagel DOSAGE FORM/ STRENGTH: 800 mg tablet Sevelamer Carbonate Brand(s): Accel-Sevelamer DOSAGE FORM/ STRENGTH: 800 mg tablet Sevelamer Carbonate Brand(s): Renvela DOSAGE FORM/ STRENGTH: 800 mg tablet, 0.8 g powder sachet, 2.4 g powder sachet Updated: June 7, 2021 i) For the treatment of hyperphosphatemia associated with end-stage renal disease (ESRD) where patients are on dialysis and have a sustained serum phosphate > 1.8 mmol/L AND adjusted serum calcium > 2.65 mmol/L; OR ii) For dialysis patients experiencing hyperphosphatemia (sustained serum phosphate levels >1.8 mmol/L) who have calciphylaxis and/or evidence of coronary artery calcification. 466 Notes: 1. Calcium and phosphate levels provided to demonstrate sustained elevations should be at least 4 weeks apart. 2. Patients who demonstrate reduction of phosphate levels while on a calcium binder but who experience adjusted serum calcium > 2.65 mmol/L must provide supporting laboratory levels before treatment and while on treatment and should include the dose(s) of calcium-based binder used. Exclusion Criteria: Sevelamer will not be reimbursed in the following cases: Use in combination therapy with another funded non-calcium-based phosphate binder (e.g. lanthanum carbonate hydrate, sucroferric oxyhydroxide, other sevelamer formulations) Duration of approval: lifetime On a case-by-case basis, requests may be considered for sevelamer under the EAP for a patient with serum phosphate less than 1.8mmol/L and calcium values less than 2.65 mmol/L. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 466, record 303, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Nat-Lanthanum · DIN 02498766 Manufacturer: Natco Pharma (Canada) Inc.; listing date 2020-07-31 Health Canada: Marketed since 2020-07-21 · brand NAT-LANTHANUM · ATC V03AE03 LANTHANUM CARBONATE · form Tablet (chewable) · route Oral · ingredients LANTHANUM (LANTHANUM CARBONATE DIHYDRATE) 750 MG · company Natco pharma (canada) inc · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02498766). DIN 02498766: Nat-Lanthanum Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 401800007; group id 550; item number 1484; lccId None; manufacturer id NAT Source form: Chew Tab; strength: 750mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $3.6219; ministry $3.6219 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02498766 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98845

Interchangeable products

Fosrenol · DIN 02287161 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02498766

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Lanthanum Brand(s): Fosrenol and Generics DOSAGE FORM/ STRENGTH: 250 mg, 500 mg, 750 mg, 1000 mg Chewable tablet Sevelamer Hydrochloride Brand(s): Renagel DOSAGE FORM/ STRENGTH: 800 mg tablet Sevelamer Carbonate Brand(s): Accel-Sevelamer DOSAGE FORM/ STRENGTH: 800 mg tablet Sevelamer Carbonate Brand(s): Renvela DOSAGE FORM/ STRENGTH: 800 mg tablet, 0.8 g powder sachet, 2.4 g powder sachet Updated: June 7, 2021 i) For the treatment of hyperphosphatemia associated with end-stage renal disease (ESRD) where patients are on dialysis and have a sustained serum phosphate > 1.8 mmol/L AND adjusted serum calcium > 2.65 mmol/L; OR ii) For dialysis patients experiencing hyperphosphatemia (sustained serum phosphate levels >1.8 mmol/L) who have calciphylaxis and/or evidence of coronary artery calcification. 466 Notes: 1. Calcium and phosphate levels provided to demonstrate sustained elevations should be at least 4 weeks apart. 2. Patients who demonstrate reduction of phosphate levels while on a calcium binder but who experience adjusted serum calcium > 2.65 mmol/L must provide supporting laboratory levels before treatment and while on treatment and should include the dose(s) of calcium-based binder used. Exclusion Criteria: Sevelamer will not be reimbursed in the following cases: Use in combination therapy with another funded non-calcium-based phosphate binder (e.g. lanthanum carbonate hydrate, sucroferric oxyhydroxide, other sevelamer formulations) Duration of approval: lifetime On a case-by-case basis, requests may be considered for sevelamer under the EAP for a patient with serum phosphate less than 1.8mmol/L and calcium values less than 2.65 mmol/L. EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 466, record 303, corpus 2025-01-01; name match only, not an eligibility decision

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

Nat-Lanthanum · DIN 02498774 Manufacturer: Natco Pharma (Canada) Inc.; listing date 2020-07-31 Health Canada: Marketed since 2020-07-21 · brand NAT-LANTHANUM · ATC V03AE03 LANTHANUM CARBONATE · form Tablet (chewable) · route Oral · ingredients LANTHANUM (LANTHANUM CARBONATE DIHYDRATE) 1000 MG · company Natco pharma (canada) inc · schedule Prescription

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02498774). DIN 02498774: Nat-Lanthanum Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 401800008; group id 550; item number 1485; lccId None; manufacturer id NAT Source form: Chew Tab; strength: 1000mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $4.8018; ministry $4.8018 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02498774 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98846

Interchangeable products

Fosrenol · DIN 02287188 · not recorded

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02498774

Shortage record checked 2026-09-13T08:10:21.292534+00:00